IL101611A - Process for the purification of hyaluronic acid and fraction of pure hyaluronic acid for ophthalmic use - Google Patents

Process for the purification of hyaluronic acid and fraction of pure hyaluronic acid for ophthalmic use

Info

Publication number: IL101611A
Authority: IL; Israel
Prior art keywords: hyaluronic acid; fraction; salt; solution; sodium
Prior art date: 1991-04-19

Application number

IL10161192A

Other languages

English (en)

Original Assignee

Fidia Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-04-19

Filing date

1992-04-16

Publication date

1996-06-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11389548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL101611(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-04-16 Application filed by Fidia Spa filed Critical Fidia Spa

1995-04-20 Priority to IL11345395A priority Critical patent/IL113453A/en

1996-06-18 Publication of IL101611A publication Critical patent/IL101611A/en

Links

229920002674 hyaluronan Polymers 0.000 title claims abstract description 77
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 69
229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 69
238000000034 method Methods 0.000 title claims abstract description 68
230000008569 process Effects 0.000 title claims abstract description 22
238000000746 purification Methods 0.000 title abstract description 19
238000001356 surgical procedure Methods 0.000 claims abstract description 49
159000000000 sodium salts Chemical class 0.000 claims abstract description 20
150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 19
238000002360 preparation method Methods 0.000 claims abstract description 11
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 80
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 77
239000000243 solution Substances 0.000 claims description 54
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
239000011780 sodium chloride Substances 0.000 claims description 46
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 36
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 28
239000002244 precipitate Substances 0.000 claims description 27
229910052742 iron Inorganic materials 0.000 claims description 26
-1 iron ions Chemical class 0.000 claims description 23
238000000605 extraction Methods 0.000 claims description 22
229920002385 Sodium hyaluronate Polymers 0.000 claims description 21
229940010747 sodium hyaluronate Drugs 0.000 claims description 21
150000003839 salts Chemical class 0.000 claims description 20
239000007864 aqueous solution Substances 0.000 claims description 19
230000001954 sterilising effect Effects 0.000 claims description 19
238000004659 sterilization and disinfection Methods 0.000 claims description 18
239000000203 mixture Substances 0.000 claims description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
229960001927 cetylpyridinium chloride Drugs 0.000 claims description 15
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical group [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 15
239000000284 extract Substances 0.000 claims description 14
208000002177 Cataract Diseases 0.000 claims description 13
239000002904 solvent Substances 0.000 claims description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
239000003960 organic solvent Substances 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 11
239000012528 membrane Substances 0.000 claims description 11
150000002500 ions Chemical class 0.000 claims description 10
239000011347 resin Substances 0.000 claims description 10
229920005989 resin Polymers 0.000 claims description 10
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical group C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 9
238000002835 absorbance Methods 0.000 claims description 9
239000000061 acid fraction Substances 0.000 claims description 9
230000000670 limiting effect Effects 0.000 claims description 9
DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical group CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 claims description 8
238000005406 washing Methods 0.000 claims description 8
210000001557 animal structure Anatomy 0.000 claims description 7
238000001914 filtration Methods 0.000 claims description 7
239000000797 iron chelating agent Substances 0.000 claims description 7
229940075525 iron chelating agent Drugs 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 6
230000002797 proteolythic effect Effects 0.000 claims description 6
229920002683 Glycosaminoglycan Polymers 0.000 claims description 5
108090000526 Papain Proteins 0.000 claims description 5
239000004365 Protease Substances 0.000 claims description 5
230000007717 exclusion Effects 0.000 claims description 5
239000007943 implant Substances 0.000 claims description 5
229940055729 papain Drugs 0.000 claims description 5
235000019834 papain Nutrition 0.000 claims description 5
102000057297 Pepsin A Human genes 0.000 claims description 4
108090000284 Pepsin A Proteins 0.000 claims description 4
108010059712 Pronase Proteins 0.000 claims description 4
108090000631 Trypsin Proteins 0.000 claims description 4
102000004142 Trypsin Human genes 0.000 claims description 4
238000000502 dialysis Methods 0.000 claims description 4
229940111202 pepsin Drugs 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
238000003860 storage Methods 0.000 claims description 4
239000012588 trypsin Substances 0.000 claims description 4
229960001322 trypsin Drugs 0.000 claims description 4
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims description 3
102000009027 Albumins Human genes 0.000 claims description 3
108010088751 Albumins Proteins 0.000 claims description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
239000000010 aprotic solvent Substances 0.000 claims description 3
239000008366 buffered solution Substances 0.000 claims description 3
229960001305 cysteine hydrochloride Drugs 0.000 claims description 3
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
239000011368 organic material Substances 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
239000011593 sulfur Substances 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
230000001376 precipitating effect Effects 0.000 claims description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
238000001035 drying Methods 0.000 claims 1
230000003381 solubilizing effect Effects 0.000 claims 1
208000035965 Postoperative Complications Diseases 0.000 abstract description 12
230000002757 inflammatory effect Effects 0.000 abstract description 9
KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 93
229940089982 healon Drugs 0.000 description 59
239000000047 product Substances 0.000 description 37
230000004410 intraocular pressure Effects 0.000 description 27
210000001508 eye Anatomy 0.000 description 24
238000011282 treatment Methods 0.000 description 22
239000000126 substance Substances 0.000 description 14
238000012360 testing method Methods 0.000 description 13
239000012071 phase Substances 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
239000002738 chelating agent Substances 0.000 description 10
210000000265 leukocyte Anatomy 0.000 description 10
150000003863 ammonium salts Chemical class 0.000 description 9
150000004676 glycans Chemical class 0.000 description 9
239000007788 liquid Substances 0.000 description 9
238000000108 ultra-filtration Methods 0.000 description 9
230000000694 effects Effects 0.000 description 8
210000003743 erythrocyte Anatomy 0.000 description 8
238000002513 implantation Methods 0.000 description 8
229920001282 polysaccharide Polymers 0.000 description 8
239000005017 polysaccharide Substances 0.000 description 8
230000002980 postoperative effect Effects 0.000 description 8
241000282693 Cercopithecidae Species 0.000 description 7
238000005119 centrifugation Methods 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000011521 glass Substances 0.000 description 6
239000000843 powder Substances 0.000 description 6
230000001681 protective effect Effects 0.000 description 6
JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 6
239000003190 viscoelastic substance Substances 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
238000013019 agitation Methods 0.000 description 5
210000002159 anterior chamber Anatomy 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004087 cornea Anatomy 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
210000002889 endothelial cell Anatomy 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
239000000463 material Substances 0.000 description 5
238000000386 microscopy Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
230000004304 visual acuity Effects 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
238000001134 F-test Methods 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
210000002808 connective tissue Anatomy 0.000 description 4
238000009472 formulation Methods 0.000 description 4
229940014041 hyaluronate Drugs 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
229940045641 monobasic sodium phosphate Drugs 0.000 description 4
229910000403 monosodium phosphate Inorganic materials 0.000 description 4
235000019799 monosodium phosphate Nutrition 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
241000894007 species Species 0.000 description 4
239000003206 sterilizing agent Substances 0.000 description 4
VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 4
239000008215 water for injection Substances 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000032683 aging Effects 0.000 description 3
210000001742 aqueous humor Anatomy 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
210000000795 conjunctiva Anatomy 0.000 description 3
239000013256 coordination polymer Substances 0.000 description 3
229940061607 dibasic sodium phosphate Drugs 0.000 description 3
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
210000000871 endothelium corneal Anatomy 0.000 description 3
108700039708 galantide Proteins 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000001558 permutation test Methods 0.000 description 3
229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000017423 tissue regeneration Effects 0.000 description 3
210000004127 vitreous body Anatomy 0.000 description 3
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
206010010741 Conjunctivitis Diseases 0.000 description 2
206010011033 Corneal oedema Diseases 0.000 description 2
208000031354 Hyphema Diseases 0.000 description 2
241000282567 Macaca fascicularis Species 0.000 description 2
208000001344 Macular Edema Diseases 0.000 description 2
206010025415 Macular oedema Diseases 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
206010036346 Posterior capsule opacification Diseases 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
229920000153 Povidone-iodine Polymers 0.000 description 2
229910000831 Steel Inorganic materials 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
239000006286 aqueous extract Substances 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
229920001222 biopolymer Polymers 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
201000004778 corneal edema Diseases 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003544 deproteinization Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
238000002224 dissection Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
229920001971 elastomer Polymers 0.000 description 2
230000006862 enzymatic digestion Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000010200 folin Substances 0.000 description 2
150000003278 haem Chemical class 0.000 description 2
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000009616 inductively coupled plasma Methods 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000002955 isolation Methods 0.000 description 2
201000010230 macular retinal edema Diseases 0.000 description 2
235000013372 meat Nutrition 0.000 description 2
238000002483 medication Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000002674 ointment Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229960001621 povidone-iodine Drugs 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
125000001453 quaternary ammonium group Chemical group 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000013558 reference substance Substances 0.000 description 2
230000011514 reflex Effects 0.000 description 2
210000003786 sclera Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
239000010959 steel Substances 0.000 description 2
238000012353 t test Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
229940006076 viscoelastic substance Drugs 0.000 description 2
WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
241000282709 Aotus trivirgatus Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
208000024304 Choroidal Effusions Diseases 0.000 description 1
206010008783 Choroidal detachment Diseases 0.000 description 1
BYMMIQCVDHHYGG-UHFFFAOYSA-N Cl.OP(O)(O)=O Chemical compound Cl.OP(O)(O)=O BYMMIQCVDHHYGG-UHFFFAOYSA-N 0.000 description 1
206010010719 Conjunctival haemorrhage Diseases 0.000 description 1
206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
206010010726 Conjunctival oedema Diseases 0.000 description 1
206010052119 Cyclitic membrane Diseases 0.000 description 1
241000722985 Fidia Species 0.000 description 1
238000000729 Fisher's exact test Methods 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010022948 Iris atrophy Diseases 0.000 description 1
241001262617 Japonica Species 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010040943 Skin Ulcer Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
208000034698 Vitreous haemorrhage Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001741 anti-phlogistic effect Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000006229 carbon black Substances 0.000 description 1
229960004830 cetylpyridinium Drugs 0.000 description 1
NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 1
230000009920 chelation Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229920005556 chlorobutyl Polymers 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
229960002433 cysteine Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000000806 elastomer Substances 0.000 description 1
230000005518 electrochemistry Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000000494 facilitatory effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000036449 good health Effects 0.000 description 1
159000000011 group IA salts Chemical class 0.000 description 1
230000035876 healing Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
201000004614 iritis Diseases 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229940087766 mydriacyl Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
238000011403 purification operation Methods 0.000 description 1
238000001226 reprecipitation Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000001223 reverse osmosis Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
201000008525 senile cataract Diseases 0.000 description 1
231100000019 skin ulcer Toxicity 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
210000001760 tenon capsule Anatomy 0.000 description 1
125000005207 tetraalkylammonium group Chemical group 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000007669 thermal treatment Methods 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000003144 traumatizing effect Effects 0.000 description 1
229960004791 tropicamide Drugs 0.000 description 1
239000008154 viscoelastic solution Substances 0.000 description 1
210000002395 vitreous cell Anatomy 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Materials Engineering (AREA)
Polymers & Plastics (AREA)
Ophthalmology & Optometry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL10161192A 1991-04-19 1992-04-16 Process for the purification of hyaluronic acid and fraction of pure hyaluronic acid for ophthalmic use IL101611A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
IL11345395A IL113453A (en)	1991-04-19	1995-04-20	Procedure for the purification of hyaluronic acid

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ITPD910077A IT1247175B (it)	1991-04-19	1991-04-19	Procedimento per la purificazione di acido ialuronico e frazione di acido ialuronico puro per uso oftalmico.

Publications (1)

Publication Number	Publication Date
IL101611A true IL101611A (en)	1996-06-18

Family

ID=11389548

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL10161192A IL101611A (en)	1991-04-19	1992-04-16	Process for the purification of hyaluronic acid and fraction of pure hyaluronic acid for ophthalmic use
IL11345395A IL113453A (en)	1991-04-19	1995-04-20	Procedure for the purification of hyaluronic acid

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL11345395A IL113453A (en)	1991-04-19	1995-04-20	Procedure for the purification of hyaluronic acid

Country Status (24)

Country	Link
US (1)	US5559104A (fi)
EP (1)	EP0535200B1 (fi)
JP (1)	JP2580458B2 (fi)
KR (1)	KR0178544B1 (fi)
AT (1)	ATE186307T1 (fi)
AU (1)	AU653022B2 (fi)
BR (1)	BR9205240A (fi)
CA (1)	CA2084875C (fi)
CZ (1)	CZ282248B6 (fi)
DE (1)	DE69230242T2 (fi)
DK (1)	DK0535200T3 (fi)
ES (1)	ES2092971T3 (fi)
FI (1)	FI104973B (fi)
GR (1)	GR3032434T3 (fi)
HU (1)	HU215193B (fi)
IL (2)	IL101611A (fi)
IT (1)	IT1247175B (fi)
NO (1)	NO305520B1 (fi)
PL (1)	PL168477B1 (fi)
RU (1)	RU2128666C1 (fi)
SG (1)	SG46515A1 (fi)
SK (1)	SK280191B6 (fi)
UA (1)	UA27229C2 (fi)
WO (1)	WO1992018543A1 (fi)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1274984B (it) *	1994-12-09	1997-07-29	Technopharma Sa	Soluzioni viscosizzate con ialuronato di sodio per l'uso come fluido maschera nella fotocheratectomia terapeutica mediante laser a accimeri
IT1282219B1 (it) *	1995-12-20	1998-03-16	Fidia Advanced Biopolymers Srl	Processo chimico fisico combinato per la preparazione di frazioni di acido ialuronico a basso peso molecolare caratterizzate da bassa
IT1287967B1 (it)	1996-10-17	1998-09-10	Fidia Spa In Amministrazione S	Preparazioni farmaceutiche per uso anestetico locale
IT1291452B1 (it)	1997-04-14	1999-01-11	Fidia Advanced Biopolymers Srl	Rivestimento a base di acido ialuronico e suoi derivati per la protezione di parti elettroniche da agenti esterni
US6919076B1 (en)	1998-01-20	2005-07-19	Pericor Science, Inc.	Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en)	1998-01-20	2005-10-25	Pericor Science, Inc.	Linkage of agents to body tissue using microparticles and transglutaminase
IL139354A (en)	1998-05-29	2005-08-31	Bone Care Internat Inc	Method for making hydroxy-25 ene-vitamin d compounds
DK172900B1 (da)	1998-12-18	1999-09-27	Per Julius Nielsen	Præparat samt kit til brug ved intraoculære operationer
IT1306644B1 (it)	1999-04-08	2001-10-02	Fidia Advanced Biopolymers Srl	Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico.
RU2163123C2 (ru) *	1999-05-26	2001-02-20	Уфимский научно-исследовательский институт глазных болезней	Глазные капли
RU2148404C1 (ru) *	1999-07-08	2000-05-10	Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза"	Фармацевтическая композиция для медикаментозного расширения зрачка в офтальмологии
RU2147876C1 (ru) *	1999-07-08	2000-04-27	Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза"	Фармацевтическая композиция для обезболивания в офтальмологии
RU2186786C1 (ru) *	2001-03-26	2002-08-10	Воронежская государственная технологическая академия	Способ получения гиалуроновой кислоты
KR100836733B1 (ko) *	2002-11-15	2008-06-10	코오롱생명과학 주식회사	히알우론산 나트륨의 회수방법 및 그를 위한 장치
RU2234310C1 (ru) *	2003-01-21	2004-08-20	Гусева Ольга Юрьевна	Способ приготовления вискоэластичного протектора эндотелия роговицы
US20040167480A1 (en) *	2003-02-21	2004-08-26	Advanced Medical Optics, Inc.	Administration of multiple viscoelastic solutions with a multi-compartment syringe
US20040180025A1 (en) *	2003-03-12	2004-09-16	New Life Resources, Llc	Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US6946551B2 (en) *	2003-03-12	2005-09-20	New Life Resources, Llc	Preparation of hyaluronic acid from eggshell membrane
US20080063677A1 (en) *	2004-03-10	2008-03-13	New Life Resources, Llc	Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
RU2325902C2 (ru) *	2003-10-27	2008-06-10	Федеральное государственное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А.Илизарова Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "РНЦ "ВТО" им.акад. Г.А. Илизарова Росмедтехнологий")	Способ выделения гликозаминогликанов из минерализованной соединительной ткани
US8580315B2 (en) *	2004-03-10	2013-11-12	Esm Technologies, Llc	Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations
US20050266390A1 (en) *	2004-06-01	2005-12-01	Yuichiro Ueda	Processes for removing cells and cell debris from tissue and tissue constructs used in transplantation and tissue reconstruction
KR100577075B1 (ko) *	2004-06-16	2006-05-08	주식회사 티앤라이프시스템	칼슘염 및 인산염, 또는 인산칼슘염을 이용한 히아루론산정제방법
US7094775B2 (en)	2004-06-30	2006-08-22	Bone Care International, Llc	Method of treating breast cancer using a combination of vitamin D analogues and other agents
US8021684B2 (en) *	2004-07-09	2011-09-20	Ferrosan Medical Devices A/S	Haemostatic composition comprising hyaluronic acid
RU2280041C1 (ru) *	2005-04-21	2006-07-20	Общество с ограниченной ответственностью Научно-производственное предприятие "Тульская индустрия ЛТД"	Способ получения водорастворимых солевых комплексов гиалуроновой кислоты (варианты)
DE102005030011A1 (de) *	2005-06-17	2006-12-21	Aesculap Ag & Co. Kg	Verfahren zur Herstellung von sterilen Polysaccharidlösungen
ITPD20050242A1 (it)	2005-08-03	2007-02-04	Fidia Farmaceutici	Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
ITMI20061668A1 (it) *	2006-09-01	2008-03-02	Schiena Michele Giuseppe Di	Composizione a base di acido ialuronico e suoi sali per il trattamento di lesioni epiteliali
KR101509139B1 (ko) *	2006-11-23	2015-04-08	주식회사 엘지생명과학	히알루론산의 정제방법
KR100894042B1 (ko) *	2007-04-13	2009-04-20	가톨릭대학교 산학협력단	설파살라진-히알루론산 혼합물의 제조방법 및 이로부터얻어진 혼합물을 포함하는 후발성 백내장 억제용 조성물
US9089592B2 (en)	2007-04-26	2015-07-28	Seikagaku Corporation	Method for micro-incision cataract surgery, a method of evaluation of a viscoelastic material, a composition for evaluation of a viscoelastic material and a method for evaluation using the composition
US8759321B2 (en) *	2007-06-13	2014-06-24	Bausch & Lomb Incorporated	Ophthalmic composition with hyaluronic acid and polymeric biguanide
MX338879B (es)	2007-11-13	2016-05-04	Bio Technology General Israel Ltd	Proceso de esterilizacion por filtracion en estado diluido para biopolimeros viscoelasticos.
US8119112B2 (en) *	2008-01-31	2012-02-21	Bausch & Lomb Incorporated	Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid
US9096819B2 (en)	2008-01-31	2015-08-04	Bausch & Lomb Incorporated	Ophthalmic compositions with an amphoteric surfactant and an anionic biopolymer
WO2009124266A2 (en)	2008-04-04	2009-10-08	University Of Utah Research Foundation	Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US20100286010A1 (en) *	2008-09-03	2010-11-11	Erning Xia	Ophthalmic Compositions with Hyaluronic Acid
US20100086512A1 (en)	2008-10-02	2010-04-08	Rolf Schaefer	Mucomimetic compositions and uses therefore
US20100178317A1 (en) *	2009-01-09	2010-07-15	Burke Susan E	Lens Care Solutions with Hyaluronic Acid
WO2012118193A1 (ja) *	2011-03-02	2012-09-07	電気化学工業株式会社	ヒアルロン酸またはその塩を含む水溶液
KR20140024863A (ko) *	2011-03-02	2014-03-03	덴키 가가쿠 고교 가부시기가이샤	히알루론산 또는 히알루론산염을 포함하는 수용액
KR20140024862A (ko) *	2011-03-02	2014-03-03	덴키 가가쿠 고교 가부시기가이샤	히알루론산 또는 히알루론산염을 포함하는 수용액
CN103547273A (zh) *	2011-03-02	2014-01-29	电气化学工业株式会社	一种向具有树脂制筒部的注射器内注入含透明质酸或透明质酸盐的水溶液而成的预充式注射器
WO2012118192A1 (ja) *	2011-03-02	2012-09-07	電気化学工業株式会社	ヒアルロン酸またはその塩を含む水溶液
EP2688402B1 (en)	2011-03-23	2018-10-24	University of Utah Research Foundation	Means for treating or preventing urological inflammation
RU2477138C1 (ru) *	2011-11-02	2013-03-10	Общество с ограниченной ответственностью Научно-производственное предприятие "Тульская индустрия ЛТД"	Способ получения заполняющего материала для пластической хирургии и инструментальной косметологии, заполняющий материал и способ введения заполняющего материала в проблемную зону
ITMI20120664A1 (it)	2012-04-20	2013-10-21	Anika Therapeutics Srl	Biomateriali a base di gellano per l'uso come filler in chirurgia
US10723812B2 (en)	2014-02-06	2020-07-28	New York University	Method for separating hyaluronan and quantifying its molecular mass distribution in biological samples
IT201600079633A1 (it) *	2016-07-28	2018-01-28	Fidia Farm Spa	Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico
US11337994B2 (en)	2016-09-15	2022-05-24	University Of Utah Research Foundation	In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
CN111228653A (zh)	2018-11-13	2020-06-05	格莱科米拉治疗公司	用电离辐射加强癌症治疗的方法
IT201900019724A1 (it) *	2019-10-24	2021-04-24	Bmg Pharma S P A	“procedimento in solvente organico per la purificazione dell’acido ialuronico sale sodico”
WO2021110975A1 (en)	2019-12-05	2021-06-10	Cis Pharma Ag	High hyaluronate multi-purpose disinfection solutions for ophthalmic applications
RU2765951C1 (ru) *	2021-05-14	2022-02-07	Общество с ограниченной ответственностью "АВЕО"	Способ очистки гиалуроната от эндотоксинов
WO2023030435A1 (en)	2021-09-01	2023-03-09	Shanghai Qisheng Biological Preparation Co., Ltd.	Cartilage regeneration using injectable, in situ polymerizable collagen compositions containing chondrocytes or stem cells
CN118434792A (zh)	2021-12-28	2024-08-02	上海其胜生物制剂有限公司	透明质酸-胶原共聚物组合物及其医学应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT252264B (de) *	1965-03-17	1967-02-10	Etapharm Chem Pharm Lab Ges M	Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates
US4141973A (en) *	1975-10-17	1979-02-27	Biotrics, Inc.	Ultrapure hyaluronic acid and the use thereof
US4766348A (en) *	1983-06-09	1988-08-23	Gte Products Corporation	Single-ended metal halogen lamp and fabrication process employing ionization potential selection of additive gases
CH666897A5 (fr) *	1983-10-11	1988-08-31	Fidia Spa	Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques.
US5093487A (en) *	1986-01-06	1992-03-03	Mobay Corporation	Low viscosity high molecular weight filter sterilizable hyaluronic acid
NO161573C (no) *	1983-11-25	1989-08-30	Miles Inc	Fremgangsmaate til fremstilling av hyaluronsyre.
JPS6121241A (ja) *	1984-07-10	1986-01-29	オリエンタル建設株式会社	プレストレストコンクリ−ト部材組立式ラ−メン構造体における多スパン梁の構築方法
US4784990A (en) *	1985-01-18	1988-11-15	Bio-Technology General Corporation	High molecular weight sodium hyaluronate
AU600257B2 (en) *	1986-03-21	1990-08-09	International Pharmaceutical Products, Inc.	Non-inflammatory hyaluronic acid fraction and process for preparing it
IT1198449B (it) *	1986-10-13	1988-12-21	F I D I Farmaceutici Italiani	Esteri di alcoli polivalenti di acido ialuronico
JPH0813847B2 (ja) *	1987-08-11	1996-02-14	日本化薬株式会社	ヒアルロン酸の分画法
JPH01210401A (ja) *	1988-02-17	1989-08-24	Mitsubishi Rayon Co Ltd	酸性多糖類の分離法
JPH0723317B2 (ja) *	1988-03-17	1995-03-15	生化学工業株式会社	角膜上皮層障害症治療剤
US4920104A (en) *	1988-05-16	1990-04-24	Medchem Products, Inc.	Sodium hyaluronate composition
JP2731545B2 (ja) *	1988-10-12	1998-03-25	電気化学工業株式会社	ヒアルロン酸の精製方法

1991
- 1991-04-19 IT ITPD910077A patent/IT1247175B/it active IP Right Grant
1992
- 1992-04-16 PL PL92297297A patent/PL168477B1/pl unknown
- 1992-04-16 SG SG1996005472A patent/SG46515A1/en unknown
- 1992-04-16 AU AU15766/92A patent/AU653022B2/en not_active Expired
- 1992-04-16 DE DE69230242T patent/DE69230242T2/de not_active Expired - Lifetime
- 1992-04-16 CZ CS923771A patent/CZ282248B6/cs not_active IP Right Cessation
- 1992-04-16 RU RU92016520A patent/RU2128666C1/ru active
- 1992-04-16 AT AT92908628T patent/ATE186307T1/de active
- 1992-04-16 IL IL10161192A patent/IL101611A/en not_active IP Right Cessation
- 1992-04-16 CA CA002084875A patent/CA2084875C/en not_active Expired - Lifetime
- 1992-04-16 KR KR1019920703262A patent/KR0178544B1/ko not_active Expired - Lifetime
- 1992-04-16 ES ES92908628T patent/ES2092971T3/es not_active Expired - Lifetime
- 1992-04-16 WO PCT/EP1992/000861 patent/WO1992018543A1/en not_active Ceased
- 1992-04-16 HU HU9204012A patent/HU215193B/hu unknown
- 1992-04-16 EP EP92908628A patent/EP0535200B1/en not_active Expired - Lifetime
- 1992-04-16 BR BR9205240A patent/BR9205240A/pt not_active Application Discontinuation
- 1992-04-16 DK DK92908628T patent/DK0535200T3/da active
- 1992-04-16 SK SK3771-92A patent/SK280191B6/sk not_active IP Right Cessation
- 1992-04-16 JP JP4507997A patent/JP2580458B2/ja not_active Expired - Lifetime
- 1992-12-16 NO NO924873A patent/NO305520B1/no not_active IP Right Cessation
- 1992-12-18 FI FI925756A patent/FI104973B/fi not_active IP Right Cessation
1993
- 1993-06-16 UA UA93002144A patent/UA27229C2/uk unknown
1995
- 1995-04-20 IL IL11345395A patent/IL113453A/en not_active IP Right Cessation
- 1995-05-11 US US08/439,437 patent/US5559104A/en not_active Expired - Lifetime
2000
- 2000-01-19 GR GR20000400131T patent/GR3032434T3/el unknown

Also Published As

Publication number	Publication date
ITPD910077A0 (it)	1991-04-19
PL297297A1 (en)	1993-09-06
CZ282248B6 (cs)	1997-06-11
CA2084875A1 (en)	1992-10-20
FI925756A0 (fi)	1992-12-18
EP0535200B1 (en)	1999-11-03
KR0178544B1 (ko)	1999-04-01
IT1247175B (it)	1994-12-12
UA27229C2 (uk)	2000-08-15
EP0535200A1 (en)	1993-04-07
HU9204012D0 (en)	1993-03-29
ITPD910077A1 (it)	1992-10-19
WO1992018543A1 (en)	1992-10-29
IL113453A0 (en)	1995-07-31
US5559104A (en)	1996-09-24
JPH05508183A (ja)	1993-11-18
ES2092971T1 (es)	1996-12-16
RU2128666C1 (ru)	1999-04-10
KR930700557A (ko)	1993-03-15
ATE186307T1 (de)	1999-11-15
PL168477B1 (pl)	1996-02-29
JP2580458B2 (ja)	1997-02-12
ES2092971T3 (es)	2000-01-01
DE69230242D1 (de)	1999-12-09
NO924873L (no)	1993-02-19
NO924873D0 (no)	1992-12-16
NO305520B1 (no)	1999-06-14
DK0535200T3 (da)	2000-05-08
HUT63186A (en)	1993-07-28
SK377192A3 (en)	1995-06-07
SG46515A1 (en)	1998-02-20
IL113453A (en)	1995-07-31
HU215193B (hu)	1998-10-28
AU1576692A (en)	1992-11-17
FI104973B (fi)	2000-05-15
SK280191B6 (sk)	1999-09-10
BR9205240A (pt)	1993-08-31
CZ377192A3 (en)	1993-05-12
DE69230242T2 (de)	2000-06-21
AU653022B2 (en)	1994-09-15
GR3032434T3 (en)	2000-05-31
FI925756L (fi)	1992-12-18
CA2084875C (en)	1998-01-06

Publication	Publication Date	Title
EP0535200B1 (en)	1999-11-03	Procedure for the purification of hyaluronic acid and fraction of pure hyaluronic acid for ophthalmic use
US5681825A (en)	1997-10-28	Surgical method
US4141973A (en)	1979-02-27	Ultrapure hyaluronic acid and the use thereof
CA2193543C (en)	2006-02-21	Sodium hyaluronate based ophthalmic formulation for use in eye surgery
EP0399156B1 (en)	1995-10-25	Sodium hyaluronate composition
Yi et al.	2002	Corneal edema after cataract surgery: incidence and etiology
RU2145882C1 (ru)	2000-02-27	Синтетический вязкоэластичный материал для применения в офтальмологии
WO1996032929A1 (en)	1996-10-24	Ophthalmic solutions containing hyaluronic acid in physiologically compatible solution
DE68906213T2 (de)	1993-08-05	Intraokular-antikoagulans.
DE60209144T2 (de)	2006-08-17	Viskoelastische ophthalmische zubereitungen enthaltend hyaluronsäure und chondroitinsulfat
JPH09235233A (ja)	1997-09-09	トレハロースを含有する眼科用医薬組成物
RU2147876C1 (ru)	2000-04-27	Фармацевтическая композиция для обезболивания в офтальмологии
Hoopes	1982	Sodium hyaluronate (Healon®) in anterior segment surgery: A review and a new use in extracapsular surgery
KR20060131938A (ko)	2006-12-20	점탄성 조성물을 포함하는 신규한 유리-라디칼 제거제,사용 방법 및 패키지
Storr‐Paulsen et al.	1991	Long‐term results of extracapsular cataract extraction with posterior chamber lens implantation: Sodium hyaluronate 1% vs hydroxypropyl methylcellulose 2%
Gaskell et al.	1991	A double blind randomized multicentre clinical trial of ‘Healon GV’compared with ‘Healon’in ECCE with IOL implantation
RU2135127C1 (ru)	1999-08-27	Раствор для защиты и лечения заболеваний и повреждений роговицы "визитин"
Genstler et al.	1983	Amvisc® in extracapsular cataract extraction
Fechner et al.	1989	Comparison of hydroxypropyl methylcellulose 2%(Adatocel®) and hyaluronic acid 1%(Healon®)
WO2025114947A1 (en)	2025-06-05	Ophthalmic pharmaceutical compositions and relative use

Legal Events

Date	Code	Title
1996-11-14	FF	Patent granted
1997-03-18	KB	Patent renewed
1998-09-24	KB	Patent renewed
2001-06-14	RH	Patent void
2002-06-30	KB	Patent renewed
2006-07-05	KB	Patent renewed
2010-10-31	KB	Patent renewed
2012-12-31	EXP	Patent expired